Gemini Therapeutics (GMTX) Stock Analysis

What Gemini Therapeutics does

Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients. Beyond this, the firm is progressing GEM307, aimed at treating systemic ailments. Established in 2015, Gemini Therapeutics' operations are based out of Cambridge, Massachusetts.

Key metrics

ETFs linked to GMTX

Broad-market and Healthcare sector ETFs an investor holding Gemini Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GMTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Gemini Therapeutics?

Gemini Therapeutics trades under the ticker GMTX on NASDAQ.

Which exchange is GMTX listed on?

GMTX is listed on NASDAQ.

What sector does Gemini Therapeutics operate in?

Gemini Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GMTX in a portfolio?

PortView shows GMTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.